Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma: report of Cohorts 2 and 4

D’Angelo SP, Demi+ G, Van Tiem BA, Duda M, Gloyd J, Cline J, Trento J
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Washington University in St. Louis, MO, USA; YL Lee-Moffitt Cancer Center, Tampa, FL, USA; National Cancer Institute, Bethesda, MD, USA; City of Hope Comprehensive Cancer Center, Duarte, CA, USA; GSK, Collegeville, PA, USA; University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background

Adoptive T-cell therapy (TCT) is a promising treatment for recurrent or metastatic solid and hematologic malignancies with encouraging activity demonstrated in a phase 1b study in patients with synovial sarcoma, melanoma, and multiple myeloma.

New York–expressed antigen (NY-ESO-1) is a member of the cancer/testis family of tumor antigens that is not present in healthy tissues.

NY-ESO-1 is expressed across multiple malignancies including 70% of tumors with synovial sarcoma. The target is expressed in bone and soft tissue sarcoma variants of the tumor in 65% of cases.

Background